Kheiron

Kheiron Medical Technologies and Microsoft Join Forces To Support Breast Cancer Detection

Retrieved on: 
Friday, November 25, 2022
Cloud, Breast, Microsoft, Hospital, Azure, Breast cancer, United Kingdom, AI, Conference on Semantics in Healthcare and Life Sciences, Privacy, Machine learning, UK Government G-Cloud, Cancer, Health care, Woman, NHS England, NHS, Internet, Radiology, England, Patient, Medical imaging, Medical device, EU, Mia, Kheiron, Temple of Azure Clouds

LONDON, Nov. 25, 2022 /PRNewswire-PRWeb/ -- Kheiron Medical Technologies announced a new technology collaboration with Microsoft that is already supporting the detection of breast cancers alongside radiologists. Kheiron, which has pioneered the development and deployment of an AI solution called Mia® to help radiologists find breast cancer earlier, is leveraging the power and scale of Microsoft's Azure Cloud to enable the global reach and impact of its technology.

Key Points: 
  • LONDON, Nov. 25, 2022 /PRNewswire-PRWeb/ -- Kheiron Medical Technologies announced a new technology collaboration with Microsoft that is already supporting the detection of breast cancers alongside radiologists.
  • Jacob West, Managing Director of Healthcare and Life Sciences at Microsoft UK, said, "Kheiron Medical's AI solution shows how cloud-based medical solutions can support the work of skilled medical professionals.
  • Founded in 2016 by Dr. Peter Kecskemethy and Tobias Rijken, Kheiron Medical Technologies is developing AI diagnostics and monitoring solutions to give every patient a better fighting chance against cancer.
  • Its initial focus is improving the outcomes for the more than two million women diagnosed globally every year with breast cancer.

Kheiron Medical Technologies Forms US Breast Medical Advisory Board; Appoints Three Leaders With Deep Track Record Advocating For Women's Health

Retrieved on: 
Wednesday, May 11, 2022
United Kingdom, School, Stanford University School of Medicine, Department, University, Mortality, MRI, Woman, Society, UC, Trailblazer, Emory University, Breast cancer, San Francisco, Social media, Patient, University of Missouri–Kansas City School of Medicine, Mammography, CEDM, Partnership, University of California, San Francisco, University of Texas Health Science Center Department of Radiology, Memorial Sloan Kettering Cancer Center, Cancer, Artificial intelligence, University of California, Davis, 2021 Essex County Council election, Machine learning, Leadership, Magnetic resonance imaging, Publication, Death, Disease, Science, Solution, CEO, Research, AI, Weill Cornell Medicine, Southern Illinois University School of Medicine, Intelligence, Medical device, Medical imaging, Radiology, Medicine, Kheiron

LONDON, May 11, 2022 /PRNewswire-PRWeb/ -- Kheiron Medical Technologies today announced the appointment of Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel to its US Breast Medical Advisory Board. These appointments reinforce Kheiron's focus on bringing its artificial intelligence solutions to the US market to help radiologists detect breast cancer earlier. Kheiron is committed to assembling an inclusive advisory board that shares its mission for creating equitable access to breast cancer screening, including among historically underserved populations. Through their work as leading authorities in breast cancer imaging, Dr. DeMartini, Dr. Morris, and Dr. Patel uniquely understand the challenges of delivering screening services and implementing AI solutions in settings ranging from underserved communities to world-class academic health centers. The US Breast Medical Advisory Board will work with Kheiron's consortium of research collaborators to serve as a crucial source of clinical partnership and expertise. Within North America, Kheiron works closely with UC San Francisco and Emory University, among others.

Key Points: 
  • Kheiron is committed to assembling an inclusive advisory board that shares its mission for creating equitable access to breast cancer screening, including among historically underserved populations.
  • The US Breast Medical Advisory Board will work with Kheiron's consortium of research collaborators to serve as a crucial source of clinical partnership and expertise.
  • Kheiron Medical Technologies has a true commitment to improving healthcare through artificial intelligence, with strong leadership, science and a global approach.
  • I am excited to participate on the US Breast Advisory Board to be a part of a revolution in breast imaging."